News
Hosted on MSN1mon
Eli Lilly in licensing pact with Alchemab for ALS programU.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...
According to deal terms announced Tuesday, Lilly is licensing Alchemab’s ATLX-1282, an antibody that the companies say brings a first-in-class approach to ALS and other neurodegenerative diseases.
Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...
Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. Lilly will pay up to $415 million in ...
Eli Lilly has added another candidate to a growing pipeline of amyotrophic lateral sclerosis (ALS) therapies, tapping UK start-up Alchemab for an antibody currently being prepared for clinical ...
Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab ...
Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results